Home › Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection
 

Keywords :   


Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection

2013-01-07 14:00:00| Merck.com - Research & Development News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDAs review to be completed in the first half of 2013. Language:  English Contact HTML:  MerckMedia Contacts:Pam Eisele, 908-423-5042Lainie Keller, 908-423-4187orInvestor Contact:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: application drug acceptance injection

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 12
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 12
28.09Hurricane Isaac Forecast Advisory Number 12
28.09Hurricane Isaac Public Advisory Number 12
28.09Summary for Hurricane Isaac (AT5/AL102024)
28.09Tropical Storm Joyce Wind Speed Probabilities Number 6
More »